Stage-adapted treatment of HIV-associated hodgkin lymphoma: Results of a prospective multicenter study

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages 4117-4123

  Hentrich, Marcus ^a   Berger, Marcel ^c   Wyen, Christoph ^f   Siehl, Jan ^d   Rockstroh, Jürgen K ^g   Müller, Markus ^c   Fätkenheuer, Gerd ^f   Seidel, Elisabeth ^a   Nickelsen, Maike ^h   Wolf, Timo ^j   Rieke, Ansgar ^k   Schürmann, Dirk ^e   Schmidmaier, Ralf ^b   Planker, Manfred ^l   Alt, Jürgen ^m   Mosthaf, Franz ⁿ   Engert, Andreas ^f   Arasteh, Keikawus ^c   Hoffmann, Christian ⁱ  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d Ärzteforum Seestrasse Medical Center   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL BONN   (Germany)

^h Asklepios Hospital St Georg   (Germany)

ⁱ IPM Study Center   (Germany)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k Klinikum Kemperhof   (Germany)

^l Helios Hospital Krefeld   (Germany)

^m UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁿ Hematology Oncology and Infectious Diseases Practice   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIV ASSOCIATED HODGKIN LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 84869392863     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.8137     Document Type: Article

References (27)

1. Herida M, Mary-Krause M, Kaphan R, et al: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21:3447-3453, 2003
2. Clifford GM, Polesel J, Rickenbach M, et al: Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97:425-432, 2005
3. Biggar RJ, Jaffe ES, Goedert JJ, et al: Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108:3786-3791, 2006
4. Powles T, Robinson D, Stebbing J, et al: Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27:884-890, 2009
5. Spina M, Berretta M, Tirelli U: Hodgkin's disease in HIV. Hematol Oncol Clin North Am 17:843-858, 2003
6. Gérard L, Galicier L, Boulanger E, et al: Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 17:81-87, 2003
7. Hoffmann C, Chow KU, Wolf E, et al: Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 124:455-462, 2004
8. Hentrich M, Maretta L, Chow KU, et al: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: Results of a multicenter study. Ann Oncol 17:914-919, 2006
9. Spina M, Gabarre J, Rossi G, et al: Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100:1984-1988, 2002
10. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
11. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010
12. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
13. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009
14. Hartmann P, Rehwald U, Salzberger B, et al: BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 14:1562-1569, 2003
15. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. Internatioal Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
16. US Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1-19, 1992
17. Xicoy B, Ribera JM, Miralles P, et al: Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 92:191-198, 2007
18. Engert A, Borchmann P, Pluetschow A, et al: Dose-escalation with BEACOPP escalated is superior to ABVD in the combined-modality treatment of early unfavorable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood 116:336, 2010 (suppl; abstr 765)
19. Gobbi PG, Levis A, Chisesi T, et al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005
20. Spina M, Rossi G, Antinori A, et al: VEBEP regimen and highly active antiretroviral therapy (HAART) in patients (pts) with HD and HIV infection (HIV-HD). Ann Oncol 19:iv152, 2008 (suppl 4; abstr 227)
21. Engert A, Ballova V, Haverkamp H, et al: Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23:5052-5060, 2005
22. Evens AM, Helenowski I, Ramsdale E, et al: A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era. Blood 119:692-695, 2012
23. Engert A, Haverkamp H, Kobe C, et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012
24. Spina M, Ribera JM, Gabarre J, et al: Hodgkin's disease and HIV-infection (HD-HIV): Prognostic factors in 596 patients (pts) within the European Group for the Study of HIV and Tumours (GECAT). Blood 116:1586, 2010 (suppl; abstr 3883)
25. Balsalobre P, Díez-Martín JL, Re A, et al: Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 27:2192-2198, 2009
26. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002
27. - non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 113:6011-6014, 2009